Topics

Lilly's 1-drug migraine business gets support with new approval

13:30 EDT 11 Oct 2019 | BioPharmaDive

An OK for Reyvow, an acute migraine drug, complements Lilly's preventive therapy Emgality and could strengthen the company's footing in an increasingly crowded market.

Original Article: Lilly's 1-drug migraine business gets support with new approval

NEXT ARTICLE

More From BioPortfolio on "Lilly's 1-drug migraine business gets support with new approval"

Quick Search

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...